dc.creator | Ciriza de los Ríos, Constanza | es |
dc.creator | Serrano Falcón, Blanca | es |
dc.creator | Argüelles Arias, Federico | es |
dc.creator | Pérez, Esperanza | es |
dc.creator | Teruel, Carlos | es |
dc.creator | Geijo, Fernando | es |
dc.creator | Rey, Enrique | es |
dc.date.accessioned | 2022-11-04T14:21:09Z | |
dc.date.available | 2022-11-04T14:21:09Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Ciriza de los Ríos, C., Serrano Falcón, B., Argüelles Arias, F., Pérez, E., Teruel, C., Geijo, F. y Rey, E. (2021). Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome. Therapeutic Advances in Gastroenterology, 14. https://doi.org/10.1177/17562848211020570. | |
dc.identifier.issn | 1756-283X | es |
dc.identifier.issn | 1756-2848 (electrónico) | es |
dc.identifier.uri | https://hdl.handle.net/11441/138984 | |
dc.description.abstract | Background: Irritable bowel syndrome with diarrhoea (IBS-D) is a frequent problem
associated with a significant socioeconomic implication. Increased gut permeability is an
important pathophysiological mechanism. A medical device containing xyloglucan (XG), pea
protein and tannins (PPT) from grape-seed extract, and xylo-oligosaccharides (XOS) has
proven restoration of intestinal barrier function. Our objective was to evaluate the efficacy and
safety of treatment with the medical device XG + PPT + XOS (XG-PPT-XOS) in adult patients
with IBS-D in a clinical setting for 6 months.
Material and methods: This was a multicentre, open-label, prospective, observational study
conducted to evaluate long-term safety and efficacy of XG-PPT-XOS. IBS-D adult patients
(Rome IV criteria) were included and received two tablets twice daily for 6 months. IBS
Symptom Severity Score (IBS-SSS) and bowel habit were registered at baseline and monthly,
until the end of follow up. Efficacy was evaluated by comparison of mean scores at each time
point.
Results: 50 patients were included, of which 19 completed the 6 months. IBS-SSS score
decreased from 312.2 ± 82.2 to 213.6 ± 109.9 (p < 0.0001) at 1 month and 192.0 ± 108.9 at
the last visit completed; diarrhoea score decreased from 45.6 ± 17.9 to 25.7 ± 17.7 and
25.3 ± 17.2 at 1 month and at the last visit completed, respectively. Pain score decreased
from 107.8 ± 49.9 at baseline to 73.2 ± 57.3 (p < 0.0001) at 1 month and bloating score
from 56.4 ± 28.8 at baseline to 42.8 ± 32.6 (p < 0.001) at 1 month, reaching 62.4 ± 56.0 and
40.4 ± 34.3, respectively, at the last visit completed. Adverse effects were mild and mostly not
related to treatment.
Conclusion: Treating IBS-D patients with XG-PPT-XOS is effective and safe in the long term
within a clinical setting, improving all IBS-D symptoms from the first month of treatment and
showing a sustained response over the term of therapy. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | SAGE Publishing | es |
dc.relation.ispartof | Therapeutic Advances in Gastroenterology, 14. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Diarrhoea | es |
dc.subject | Gut permeability | es |
dc.subject | Irritable bowel syndrome | es |
dc.subject | Mucoprotectants | es |
dc.subject | Xyloglucan | es |
dc.subject | Xylo-oligosaccharides | es |
dc.title | Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://journals.sagepub.com/doi/epub/10.1177/17562848211020570 | es |
dc.identifier.doi | 10.1177/17562848211020570 | es |
dc.journaltitle | Therapeutic Advances in Gastroenterology | es |
dc.publication.volumen | 14 | es |